Follow-up study of mezagitamab for chronic ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a previous mezagitamab study (TAK-079-3002 or TAK-079-1004).
- If you were in study TAK-079-1004, your platelets must have responded to mezagitamab.
- You cannot have a history of severe allergic reactions to mezagitamab or its ingredients.
- You cannot have had a blood clot or stroke in the last 12 months (if from study TAK-079-1004).
- You cannot have had your spleen removed in the last 3 months (if from study TAK-079-1004).
- You must not have active hepatitis B, C, or HIV (if from study TAK-079-1004).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called mezagitamab for people with chronic ITP (low platelets for over a year). The medicine may help raise your platelet count and reduce bleeding risk.
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
Hear when a new Immune Thrombocytopenic Purpura (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.